Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of ...

Summary by Enid News & Eagle
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx Pharmaceuticals is developing NRX-101, a fixed dose combination of DCS+lurasidone for the augmentation of TMS…

1 Articles

Enid News & EagleEnid News & Eagle
Lean Left

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of ...

D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx Pharmaceuticals is developing NRX-101, a fixed dose combination of DCS+lurasidone for the augmentation of TMS…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Monday, June 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Enid icon

Enid

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal